GBC Blog

The Superbug Crisis Heats Up

With superbugs causing upwards of 35,000 deaths per year, the global antibiotic crisis is intensifying, says the World Health Organization (WHO)—and depending which direction policymakers go, antimicrobial resistance (AMR) could either be relieved or exacerbated by policy.  The problem: “Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant…

Read More

Improving Cancer Screening Programs

Science  10 Jan 2020: Vol. 367, Issue 6474, pp. 143-144, Mette Kalager & Michael Bretthauer National cancer screening programs, such as mammography for breast cancer, are widely implemented to reduce cancer incidence and mortality in high-income countries. Their introduction is also being considered in low- and middle-income countries. For many cancer types, the benefits and harms…

Read More

FDA Proposes Safer Technologies Program For Medical Devices (STeP)

The FDA’s Center for Devices and Radiological Health (CDRH) recently released draft guidance — Safer Technologies Program for Medical Devices, or STeP — for the purpose of public comment. In the guidance, the FDA states its belief that STeP “will help patients have more timely access to these medical devices and device-led combination products by…

Read More

New Blood Test Can Detect Multiple Types of Cancer

30 SEP 19, Georgia Green – A new blood test has been shown to identify different cancer types with a high degree of accuracy. When cancer cells die, they shed their DNA into the blood. Previous diagnostic tests work by identifying the genetic mutations present in the cancer cell DNA. However, this technique is limited…

Read More

India To Enhance Oversight Of Medical Devices

Gunjan Bagla, Amritt, Inc., September 25, 2019 India’s Central Drugs Standard Control Organization (CDSCO), the country’s national regulatory authority for both drugs and medical devices (i.e., India’s equivalent of the United States’ FDA) is acting on a report submitted by its internal Drugs Technical Advisory Board (DTAB) to form a new division under the CDSCO.…

Read More

Asia-Pacific In-Vitro Diagnostics Market is Expected to Reach $19.0 Billion

Surge in government initiatives, rise in R&D activities for advanced diagnostics techniques, improvement in healthcare infrastructure, and rising per capita healthcare expenditure are the factors driving the growth of the Asia Pacific IVD market. The reagent segment is expected to maintain dominance, accounting for around three-fifth of the overall Asia-Pacific IVD market. According to a new…

Read More

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

Epigenomics AG, BERLIN, July 24, 2019 (GLOBE NEWSWIRE) — Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new study results suggesting that Epi proColon®, a CRC screening test approved for patients who are unwilling or unable…

Read More

Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer

Array BioPharma, based in Boulder, Colorado, announced positive results from its Phase III BEACON CRC trial. The trial evaluated a triple combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovia (binimetinib), a MEK inhibitor, and Erbitux (cetuximab), an anti-EGFR antibody, in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC) after one or two lines of therapy.…

Read More

Ariana to Present Data at AACR 2019 on Using Artificial Intelligence to Simulate Patient Stratification in Clinical Trials and Identify Companion Biomarkers for Combination Therapy.

Ariana Pharma, a leading digital health Company focused on developing advanced therapeutic decision support systems, will present its latest results on combination therapy biomarker identification using KEM® Artificial Intelligence applied to xenograft mouse model (PDX) based clinical trial simulation, in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta,…

Read More